SANUWAVE Health (SNWV) 10-Q 16 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 04, 2016
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	1,417,663
Trading Symbol	snwv
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		104,178,421
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 authorized; 6,175 shares issued and 0 shares outstanding in 2016 and 2015 (Note 10)
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 authorized; 6,175 shares issued and 0 shares outstanding in 2016 and 2015 (Note 10)
Undesignated Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 authorized; 6,175 shares issued and 0 shares outstanding in 2016 and 2015 (Note 10)
Cash and cash equivalents	$ 604,135	$ 152,930
Accounts receivable, net of allowance for doubtful accounts of $10,015 in 2016 and $8,963 in 2015	46,032	74,454
Inventory	258,495	284,908
Prepaid expenses	147,518	123,988
TOTAL CURRENT ASSETS	1,056,180	636,280
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation	3,392	4,228
OTHER ASSETS	11,191	11,097
INTANGIBLE ASSETS, at cost, less accumulated amortization (Note 4)	230,067	306,756
TOTAL ASSETS	1,300,830	958,361
Accounts payable	356,244	509,266
Accrued expenses (Note 5)	252,003	359,374
Accrued employee compensation	286,155	241,542
Interest payable, related parties (Note 6)	182,968	$ 239,803
Notes payable, related parties (Note 6)	5,353,806
Promissory notes payable (Note 7)	100,601
Warrant liability (Note 11)	122,800	$ 138,100
TOTAL CURRENT LIABILITIES	$ 6,654,577	1,488,085
Notes Payable, Related Parties, Noncurrent		5,348,112
TOTAL LIABILITIES	$ 6,654,577	6,836,197
COMMON STOCK, par value $0.001, 350,000,000 shares authorized; 96,000,308 and 63,056,519 issued and outstanding in 2016 and 2015, respectively (Note 9)	96,000	63,057
ADDITIONAL PAID-IN CAPITAL	89,299,427	87,086,677
ACCUMULATED DEFICIT	(94,718,984)	(92,994,408)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(30,190)	(33,162)
TOTAL STOCKHOLDERS' DEFICIT	(5,353,747)	(5,877,836)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,300,830	$ 958,361

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	6,175	6,175
Preferred stock, shares issued (in shares)	6,175	6,175
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	293	293
Preferred stock, shares issued (in shares)	293	293
Preferred stock, shares outstanding (in shares)	293	0
Undesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	4,993,532	4,993,532
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Accounts receivable, allowance for doubtful accounts	$ 10,015	$ 8,963
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	96,000,308	63,056,519
Common stock, outstanding (in shares)	96,000,308	63,056,519

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
REVENUES	$ 269,324	$ 210,452
COST OF REVENUES	73,181	58,818
GROSS PROFIT	196,143	151,634
OPERATING EXPENSES
Research and development	309,955	634,623
General and administrative	499,132	566,292
Depreciation	836	925
Amortization of Intangible Assets	76,689	76,689
TOTAL OPERATING EXPENSES	886,612	1,278,529
OPERATING LOSS	(690,469)	$ (1,126,895)
OTHER INCOME (EXPENSE)
Gain on sale of assets	1,000
Gain(loss) on warrant valuation adjustment (Note 11)	(797,697)	$ 56,026
Interest expense, net	(154,187)	$ (79,344)
Amortization of debt issuance costs	(74,549)
Amortization of debt discount	(5,694)
Loss on foreign currency exchange	(2,980)	$ (8,902)
TOTAL OTHER EXPENSE	(1,034,107)	(32,220)
NET LOSS	(1,724,576)	(1,159,115)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	2,972	(12,718)
TOTAL COMPREHENSIVE LOSS	$ (1,721,604)	$ (1,171,833)
LOSS PER SHARE:
Net loss - basic and diluted (in dollars per share)	$ (0.02)	$ (0.02)
Weighted average shares outstanding - basic and diluted (in shares)	75,220,485	62,931,250

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent	$ (1,724,576)	$ (1,159,115)
Adjustments to reconcile loss from continuing operations to net cash used by operating activities
Amortization of Intangible Assets	76,689	76,689
Depreciation	836	925
Change in allowance for doubtful accounts	1,052	2,346
Stock-based compensation - employees, directors and advisors	4,500	27,827
(Gain) Loss on warrant valuation adjustment	873,118	$ (56,026)
Gain on sale of property and equipment	(1,000)
Amortization of debt issuance costs	74,549
Amortization of debt discount	5,694
Changes in assets - (increase)/decrease
Accounts receivable - trade	27,370	$ 16,561
Inventory	26,413	5,012
Prepaid expenses	(23,530)	(19,172)
Other	(94)	(80)
Changes in liabilities - increase/(decrease)
Accounts payable	(153,022)	(27,492)
Accrued expenses	(107,371)	(8,945)
Accrued employee compensation	44,613	63,108
Interest payable, related parties	(56,835)	$ (1,792)
Promissory notes - accrued interest	(79,948)
NET CASH USED BY OPERATING ACTIVITIES	(1,011,542)	$ (1,080,154)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of property and equipment	1,000
NET CASH PROVIDED BY INVESTING ACTIVITIES	1,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 2016 Equity Offering, net	1,352,775
Proceeds from Convertible Debt	106,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,458,775
EFFECT OF EXCHANGE RATES ON CASH	2,972	$ (12,718)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	451,205	(1,092,872)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	152,930	3,547,071
CASH AND CASH EQUIVALENTS, END OF PERIOD	604,135	2,454,199
SUPPLEMENTAL INFORMATION
Cash paid for interest	$ 209,549	$ 81,864

Note 1 - Nature of the Business

Note 1 - Nature of the Business	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of the Business SANUWAVE Health, Inc. and subsidiaries (the “Company”) is an acoustic pressure shock wave technology company using a patented system of noninvasive, high-energy, acoustic pressure shock waves for indications such as regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE ® The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE ® In addition to healthcare uses, our high-energy, acoustic pressure shock waves, due to their powerful pressure gradients and localized cavitational effects, may have applications in secondary and tertiary oil exploitation, for cleaning industrial waters, for sterilizing food liquids and finally for maintenance of industrial installations by disrupting biofilms formation. Our business approach will be through licensing and/or partnership opportunities.

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. Going Concern The Company does not currently generate significant recurring revenue and will require additional capital during or before the third quarter of 2016. As of March 31, 2016, the Company had an accumulated deficit of $94,718,984 and cash and cash equivalents of $604,135 . For the three months ended March 31, 2016 and 2015, the net cash used by operating activities was $1,011,542 and $1,080,154, respectively. The Company incurred a net loss of $1,724,576 for the three months ended March 31, 2016 and a net loss of $4,810,285 for the year ended December 31, 2015. The operating losses create an uncertainty about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon raising additional capital during or before the third quarter of 2016 to fund operations. Management’s plans are to obtain additional capital in 2016 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3 Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by United States generally accepted accounting principles for complete financial statements. The financial information as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month periods ended March 31, 2016 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2016. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements. Significant Accounting Policies For further information and a summary of significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 30, 2016. Recently Issued Accounting Standards New accounting pronouncements are issued by the Financial Standards Board (“FASB”) or other standards setting bodies that the Company adopts according to the various timetables the FASB specifies. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606) In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued guidance to simplify several aspects of the accounting for share-based payments transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual and interim periods beginning after December 31, 2016. Early adoption is permitted for an entity in an interim or annual period. We are currently evaluating the effect that the updated standard will have on our financial statements, but expect the guidance will add modest volatility in our equity-based compensation expense, provision for income taxes, and net income (loss).

Note 4 - Intangible Assets

Note 4 - Intangible Assets	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	4 . Intangible assets Intangible assets consist of the following: March 31, 2016 December 31, 2015 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,272,068 ) (3,195,379 ) Net intangible assets $ 230,067 $ 306,756 The aggregate amortization charged to operations was $76,689 for the three months ended March 31, 2016 and 2015.

Note 5 - Accrued Expenses

Note 5 - Accrued Expenses	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5 . Accrued expenses Accrued expenses consist of the following: March 31, 2016 December 31, 2015 Accrued former executive payment $ 100,000 $ 100,000 Accrued outside services 29,828 58,813 Accrued directors and advisors fees 27,000 - Accrued audit and tax preparation 23,376 93,500 Accrued clinical study expenses 19,773 22,777 Accrued legal professional fees 15,250 76,500 Accrued other 36,776 7,784 $ 252,003 $ 359,374

Note 6 - Notes Payable, Related

Note 6 - Notes Payable, Related Parties	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6 . Notes payable, related parties The notes payable, related parties were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. on August 1, 2005. The notes payable, related parties bear interest at 6% per annum. Quarterly interest through June 30, 2010, was accrued and added to the principal balance. Interest is paid quarterly in arrears beginning September 30, 2010. All remaining unpaid accrued interest and principal was due August 1, 2015. On June 15, 2015, the Company and HealthTronics, Inc. entered into an amendment (the “Note Amendment”) to amend certain provisions of the notes payable, related parties. The Note Amendment provides for the extension of the due date to January 31, 2017. In the period ending March 31, 2016, the Company reclassified the outstanding principal balance from non-current liabilities to current liabilities. I n connection with the Note Amendment, the Company entered into a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. The notes payable, related parties will bear interest at 8% per annum effective August 1, 2015 and during any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. The notes payable, related parties had an aggregate outstanding principal balance of $5,353,806, net of $18,937 debt discount at March 31, 2016 and $5,348,112, net of $24,631 debt discount at December 31, 2015, respectively. In addition, the Company, in connection with the Note Amendment, issued to HealthTronics, Inc. on June 15, 2015, an aggregate total of 3,310,000 warrants (the “Class K Warrants”) to purchase shares of the Company’s common stock, $0.001 par value (the “Common Stock”), at an exercise price of $0.55 per share, subject to certain anti-dilution protection. Each Class K Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after ten years. Accrued interest currently payable totaled $182,968 and $239,803 at March 31, 2016 and December 31, 2015, respectively. Interest expense on notes payable, related parties totaled $152,713 and $80,072 for the three months ended March 31, 2016 and 2015, respectively.

Note 7 - Promissory Notes Payab

Note 7 - Promissory Notes Payable	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Promissory notes payable On February 1, 2016, the Company entered into a financing transaction for the sale of an 8% Convertible Promissory Note (the “$58,300 Convertible Note”) and warrants (the “Class M Warrants”) in the principal amount of $58,300 each, with gross proceeds of $53,000 to the Company after payment of a 10% original issue discount and related professional expenses. The offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Act and Rule 506 of Regulation D thereunder. The Company did not utilize any form of general solicitation or general advertising in connection with the offering. The $58,300 Convertible Note was offered and sold to two accredited investors, with gross proceeds of $106,000 to the Company. The $58,300 Convertible Note and Class M Warrants were issued pursuant to the terms of a purchase agreement among the Company and the Investors. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on August 1, 2016. The Company has the right to prepay the convertible note and accrued interest during the first sixty (60) days following the date of issuance. During that time, the amount of any prepayment during the first sixty (60) days is 120% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent thirty (30) days. Each Class M Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire on February 21, 2021. The $58,300 Convertible Note is convertible, at any time from the issuance date, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 30% of the lowest reported sale price of the Company’s common stock for the 20 trading days immediately prior to (i) the date of the purchase agreement or (ii) the voluntary conversion date. The $58,300 Convertible Note contained put options that may require the Company to repay the debt before its maturity. The $58,300 Convertible Note holder has rights to demand repayment in the event of defaults. However, since the put is contingent on an event of default, and no principal is due until maturity, the likelihood of the other default provision is considered to be very remote especially given the term of the $58,300 Convertible Note is six months. The promissory notes payable had an aggregate outstanding balance of $100,601, net of $17,473 debt issuance costs at March 31, 2016.

Note 8 - Income Taxes

Note 8 - Income Taxes	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8 . Income taxes The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to United States federal and state and non-United States income tax examinations by tax authorities for years before 2006. At March 31, 2016, the Company had federal net operating loss (“NOL”) carryforwards of $70,096,802 for tax years through the year ended December 31, 2015, that will begin to expire in 2025. The use of deferred tax assets, including federal net operating losses, is limited to future taxable earnings. Based on the required analysis of future taxable income under the provisions of ASC 740, Income Taxes The Company’s ability to use its NOL carryforwards could be limited and subject to annual limitations. In connection with future offerings, the Company may realize a “more than 50% change in ownership” which could further limit its ability to use its NOL carryforwards accumulated to date to reduce future taxable income and tax liabilities. Additionally, because United States tax laws limit the time during which NOL carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take advantage of all or portions of its NOL carryforwards for federal income tax purposes.

Note 9 - Equity Transactions

Note 9 - Equity Transactions	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . Equity transactions 2016 Equity Offering On March 11, 2016, in conjunction with an equity offering of securities (the “2016 Equity Offering”) with select accredited investors, the Company issued an aggregate of 25,495,835 shares of common stock for an aggregate purchase price of $1,529,750. The mandatory prepayment of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company was waived by HealthTronics, Inc. for this 2016 Equity Offering. The Company, in connection with the 2016 Equity Offering, issued to the investors an aggregate of 25,495,835 warrants (the “Class L Warrants”) to purchase shares of common stock at an exercise price of $0.08 per share. Each Class L Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire on March 17, 2019. Pursuant to the terms of a Registration Rights Agreement that the Company entered with the investors in connection with the 2016 Equity Offering, the Company is required to file a registration statement that covers the shares of common stock and the shares of common stock issuable upon exercise of the Class L Warrants. The registration statement was declared effective by the SEC on February 16, 2016. Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, was a purchaser in the 2016 Equity Offering of $100,000. At the closing of the 2016 Equity Offering , the Company paid Newport Coast Securities, Inc., the placement agent for the equity offering, cash compensation based on the gross proceeds of the private placement and 2,549,584 Class L Warrants. Series A Warrant Conversion On January 13, 2016, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with certain beneficial owners (the “Investors”) of Series A warrants (the “Warrants”) to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), pursuant to which the Investors exchanged (the “Exchange”) all of their respective Warrants for either (i) shares of Common Stock or (ii) shares of Common Stock and shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value (the “Preferred Stock”). The Exchange was based on the following exchange ratio (the “Exchange Ratio”): 1 Series A Warrant = 0.4685 shares of capital stock. Investors who, as a result of the Exchange, owned in excess of 9.99% (the “Ownership Threshold”) of the outstanding Common Stock, received a mixture of Common Stock and shares of Preferred Stock. They received Common Stock up to the Ownership Threshold, and received shares of Preferred Stock beyond the Ownership Threshold (but the total shares of Common Stock and Preferred Stock issued to such holders was still based on the same Exchange Ratio). The relative rights, preferences, privileges and limitations of the Preferred Stock are as set forth in the Company’s Certificate of Designation of Series B Convertible Preferred Stock, which was filed with the Secretary of State of the State of Nevada on January 12, 2016 (the “Series B Certificate of Designation”). In the Exchange an aggregate number of 23,701,428 Warrants were exchanged for 7,447,954 shares of Common Stock and 293 shares of Preferred Stock. Pursuant to the Series B Certificate of Designation, each of the Preferred Stock shares is convertible into shares of Common Stock at an initial rate of 1 Preferred Stock share for 12,500 Common Stock shares, which conversion rate is subject to further adjustment as set forth in the Series B Certificate of Designation. Pursuant to the terms of the Series B Certificate of Designation, the holders of the Preferred Stock shares will generally be entitled to that number of votes as is equal to the number of shares of Common Stock into which the Preferred Stock may be converted as of the record date of such vote or consent, subject to the Beneficial Ownership Limitation. In connection with entering into the Exchange Agreement, the Company also entered into a Registration Rights Agreement, dated January 13, 2016, with the Investors. The Registration Rights Agreement requires that the Company file with the SEC a registration statement to register for resale the shares of the Common Stock issued in connection with the Exchange and the Common Stock issuable upon conversion of the Preferred Stock shares (the “Preferred Stock Conversion Shares”). The registration statement was declared effective by the SEC on February 16, 2016.

Note 10 - Preferred Stock

Note 10 - Preferred Stock	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Preferred Stock [Text Block]	10 . Preferred Stock The Company’s Articles of Incorporation authorize the issuance of up to 5,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by the board of directors. On January 12, 2016, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series B Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 293 shares of preferred stock, par value $0.001 per share, as Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock has a stated value of $1,000 per share. On January 13, 2016, in connection with the Series A Warrant Conversion, the Company issued 293 shares of Series B Convertible Preferred Stock (for a more detailed discussion regarding the Series A Warrant Conversion, see Note 9). Under the Certificate of Designation, holders of Series B Convertible Preferred Stock are entitled to receive dividends equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends are paid. Such holders will participate on an equal basis per-share with holders of common stock in any distribution upon winding up, dissolution, or liquidation of the Company. Holders of Series B Convertible Preferred Stock are entitled to convert each share of Series A Convertible Preferred Stock into 2,000 shares of common stock, provided that after giving effect to such conversion, such holder, together with its affiliates, shall not beneficially own in excess of 9.99% of the number of shares of common stock outstanding (the “Beneficial Ownership Limitation”). Holders of the Series B Convertible Preferred Stock are entitled to vote on all matters affecting the holders of the common stock on an “as converted” basis, provided that such holder shall only vote such shares of Series B Convertible Preferred Stock eligible for conversion without exceeding the Beneficial Ownership Limitation. On March 14, 2014, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series A Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 6,175 shares of preferred stock, par value $0.001 per share, as Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has a stated value of $1,000 per share. On March 17, 2014, in connection with a Private Placement, the Company issued 6,175 shares of Series A Convertible Preferred Stock. As of January 6, 2015 there were no outstanding shares of Series A Convertible Preferred Stock.

Note 11 - Warrants

Note 11 - Warrants	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Warrants [Text Block]	11 . Warrants A summary of the warrant activity as of March 31, 2016 and December 31, 2015, and the changes during the three months ended March 31, 2016, is presented as follows: Warrant class Outstanding as of December 31, 2015 Issued Exercised Converted Expired Outstanding as of March 31, 2016 Class E Warrants 3,576,737 - - - - 3,576,737 Class F Warrants 300,000 - - - - 300,000 Class G Warrants 1,503,409 - - - - 1,503,409 Class H Warrants 1,988,095 - - - - 1,988,095 Class I Warrants 1,043,646 - - - - 1,043,646 Class J Warrants 629,378 4,012,289 - - - 4,641,667 Class K Warrants 3,310,000 - - - - 3,310,000 Class L Warrants - 28,045,419 - - - 28,045,419 Class M Warrants - 1,943,333 - - - 1,943,333 Series A Warrants 25,951,421 - - (23,701,427 ) - 2,249,994 38,302,686 34,001,041 - (23,701,427 ) - 48,602,300 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class E Warrants $ 4.00 April 2016 Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class J Warrants $ 0.06 February 2019 Class K Warrants $ 0.55 June 2025 Class L Warrants $ 0.08 March 2019 Class M Warrants $ 0.06 February 2021 Series A Warrants $ 0.06 March 2019 The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company. The exercise price of the Class J Warrants, Class K Warrants, Class M and the Series A Warrants are subject to a “down-round” anti-dilution adjustment if the Company issues or is deemed to have issued certain securities at a price lower than the then applicable exercise price of the warrants. The exercise price of the Series A, Class J and Class M Warrants was adjusted to $0.06 due to the 2016 Equity Offering (see Note 9). The Class J Warrants and Class K Warrants may be exercised on a physical settlement or on a cashless basis. The Series A Warrants may be exercised on a physical settlement basis if a registration statement underlying the warrants is effective. If a registration statement is not effective (or the prospectus contained therein is not available for use) for the resale by the holder of the Series A Warrants, then the holder may exercise the warrants on a cashless basis. The Class J Warrants, the Class K Warrants, the Class M Warrants, the Series A Warrants and the Series B Warrants are derivative financial instruments. The estimated fair value of the Class J Warrants at the date of grant was $12,776. The related debt discount was accreted to interest expense through the maturity date of the related note. The estimated fair value of the Class K Warrants at the date of grant was $36,989 and recorded as debt discount, which will be accreted to interest expense through the maturity date of the related notes payable, related parties. The estimated fair value of the Class M Warrants at the date of grant was $9,091 and the estimated value of the conversion option of the note at the date of grant was $66,331. The related debt discount was accreted to interest expense through the maturity date of the related note. The estimated fair values of the Series A Warrants and the Series B Warrants at the date of grant were $557,733 for the warrants issued in conjunction with the 2014 Private Placement and $47,974 for the warrants issued in conjunction with the 18% Convertible Promissory Notes. The fair value of the Series A Warrants and Series B Warrants were recorded as equity issuance costs in 2014, a reduction of additional paid-in capital. The Series B Warrants expired unexercised in March 2015. The estimated fair values were determined using a binomial option pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models the Company uses to value the warrants, including the Company’s current common stock price, the remaining life of the warrants, the volatility of the Company’s common stock price, and the risk-free interest rate. In addition, as of the valuation dates, management assessed the probabilities of future financing and other re-pricing events in the binominal valuation models. A summary of the changes in the warrant liability as of March 31, 2016 and December 31, 2015, and the changes during the three months ended March 31, 2016, is presented as follows: Class J Class K Class M Series A Warrants Warrants Warrants Warrants Total Warrant liability as of December 31, 2015 $ 2,900 $ 22,700 $ - $ 112,500 $ 138,100 Issued - - 75,422 - 75,422 Change in fair value 17,600 (6,600 ) 878 (102,600 ) (90,722 ) Warrant liability as of March 31, 2016 $ 20,500 $ 16,100 $ 76,300 $ 9,900 $ 122,800

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12 . Commitments and contingencies Operating Leases Rent expense for the three months ended March 31, 2016 and 2015, was $42,519 and $33,407, respectively. Litigation The Company is involved in various legal matters that have arisen in the ordinary course of business. While the ultimate outcome of these matters is not presently determinable, it is the opinion of management that the resolution will not have a material adverse effect on the financial position or results of operations of the Company.

Note 13 - Stock-based Compensat

Note 13 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	13 . Stoc k-based compensation The Company recognized as compensation cost for all outstanding stock options granted to employees, directors and advisors, $4,500 and $27,827 for the three months ended March 31, 2016 and 2015, respectively. A summary of option activity as of March 31, 2016 and December 31, 2015, and the changes during the three months ended March 31, 2016, is presented as follows: Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 10,073,385 $ 0.62 Granted - $ - Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 10,073,385 $ 0.55 Exercisable 9,898,383 $ 0.56 The range of exercise prices for options was $0.06 to $2.00 for options outstanding at March 31, 2016 and December 31, 2015. The aggregate intrinsic value for all vested and exercisable options was $0 at March 31, 2016 and December 31, 2015. The weighted average remaining contractual term for outstanding exercisable stock options was 7.21 and 7.46 years as of March 31, 2016 and December 31, 2015, respectively. A summary of the Company’s nonvested options as of March 31, 2016 and December 31, 2015, and changes during the three months ended March 31, 2016, is presented as follows: Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 175,002 $ 0.36 Granted - $ - Vested - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 175,002 $ 0.36

Note 14 - Earnings (Loss) Per S

Note 14 - Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	14 . Earnings (loss) per share The Company calculates net income (loss) per share in accordance with ASC 260, Earnings Per Share To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the three months ended March 31, 2016 and 2015, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 62,332,963 shares and 42,199,516 shares at March 31, 2016 and 2015, respectively.

Note 15 - Subsequent Events

Note 15 - Subsequent Events	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent events 2016 Equity Offering On April 6, 2016 and April 15, 2016, in conjunction with the 2016 Equity Offering with select accredited investors, the Company issued an aggregate of 3,083,334 and 1,437,501, respectively, shares of common stock for an aggregate purchase price of $185,000 and $86,200, respectively. The Company, in connection with the 2016 Equity Offering, issued to the investors an aggregate of 4,520,835 Class L Warrants to purchase shares of common stock at an exercise price of $0.08 per share. Each Class L Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire on March 17, 2019. The Company, in connection with the 2016 Equity Offering, issued to the placement agent an aggregate of 452,083 Class L Warrants to purchase shares of common stock at an exercise price of $0.08 per share. Each Class L Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire on March 17, 2019. Preferred Stock Conversion On April 29, 2016, the holders of Series B Convertible Preferred Stock converted the outstanding 293 shares of Series B Convertible Preferred Stock into 3,657,278 shares of common stock. As of April 29, 2016, there were no outstanding shares of Series B Convertible Preferred Stock.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by United States generally accepted accounting principles for complete financial statements. The financial information as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month periods ended March 31, 2016 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2016. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards New accounting pronouncements are issued by the Financial Standards Board (“FASB”) or other standards setting bodies that the Company adopts according to the various timetables the FASB specifies. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606) - 7 - In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued guidance to simplify several aspects of the accounting for share-based payments transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual and interim periods beginning after December 31, 2016. Early adoption is permitted for an entity in an interim or annual period. We are currently evaluating the effect that the updated standard will have on our financial statements, but expect the guidance will add modest volatility in our equity-based compensation expense, provision for income taxes, and net income (loss).

Note 4 - Intangible Assets (Tab

Note 4 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2016 December 31, 2015 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,272,068 ) (3,195,379 ) Net intangible assets $ 230,067 $ 306,756

Note 5 - Accrued Expenses (Tabl

Note 5 - Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2016 December 31, 2015 Accrued former executive payment $ 100,000 $ 100,000 Accrued outside services 29,828 58,813 Accrued directors and advisors fees 27,000 - Accrued audit and tax preparation 23,376 93,500 Accrued clinical study expenses 19,773 22,777 Accrued legal professional fees 15,250 76,500 Accrued other 36,776 7,784 $ 252,003 $ 359,374

Note 11 - Warrants (Tables)

Note 11 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant class Outstanding as of December 31, 2015 Issued Exercised Converted Expired Outstanding as of March 31, 2016 Class E Warrants 3,576,737 - - - - 3,576,737 Class F Warrants 300,000 - - - - 300,000 Class G Warrants 1,503,409 - - - - 1,503,409 Class H Warrants 1,988,095 - - - - 1,988,095 Class I Warrants 1,043,646 - - - - 1,043,646 Class J Warrants 629,378 4,012,289 - - - 4,641,667 Class K Warrants 3,310,000 - - - - 3,310,000 Class L Warrants - 28,045,419 - - - 28,045,419 Class M Warrants - 1,943,333 - - - 1,943,333 Series A Warrants 25,951,421 - - (23,701,427 ) - 2,249,994 38,302,686 34,001,041 - (23,701,427 ) - 48,602,300
Schedule Of Warrant Exercise Price And Expiration Date [Table Text Block]	Exercise price/share Expiration date Class E Warrants $ 4.00 April 2016 Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class J Warrants $ 0.06 February 2019 Class K Warrants $ 0.55 June 2025 Class L Warrants $ 0.08 March 2019 Class M Warrants $ 0.06 February 2021 Series A Warrants $ 0.06 March 2019
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Class J Class K Class M Series A Warrants Warrants Warrants Warrants Total Warrant liability as of December 31, 2015 $ 2,900 $ 22,700 $ - $ 112,500 $ 138,100 Issued - - 75,422 - 75,422 Change in fair value 17,600 (6,600 ) 878 (102,600 ) (90,722 ) Warrant liability as of March 31, 2016 $ 20,500 $ 16,100 $ 76,300 $ 9,900 $ 122,800

Note 13 - Stock-based Compens25

Note 13 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 10,073,385 $ 0.62 Granted - $ - Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 10,073,385 $ 0.55 Exercisable 9,898,383 $ 0.56
Schedule of Other Share-based Compensation, Activity [Table Text Block]	Options Weighted Average Exercise Price per share Outstanding as of December 31, 2015 175,002 $ 0.36 Granted - $ - Vested - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding as of March 31, 2016 175,002 $ 0.36

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Retained Earnings (Accumulated Deficit)	$ (94,718,984)		$ (92,994,408)
Cash and Cash Equivalents, at Carrying Value	604,135	$ 2,454,199	152,930	$ 3,547,071
Net Cash Provided by (Used in) Operating Activities	(1,011,542)	(1,080,154)
Net Income (Loss) Attributable to Parent	$ (1,724,576)	$ (1,159,115)	$ (4,810,285)

Note 4 - Intangible Assets (Det

Note 4 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Amortization of Intangible Assets	$ 76,689	$ 76,689

Note 4 - Summary of Intangible

Note 4 - Summary of Intangible Assets (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Patents, at cost	$ 3,502,135	$ 3,502,135
Less accumulated amortization	(3,272,068)	(3,195,379)
Net intangible assets	$ 230,067	$ 306,756

Note 5 - Summary of Accrued Exp

Note 5 - Summary of Accrued Expenses (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accrued former executive payment	$ 100,000	$ 100,000
Accrued outside services	29,828	$ 58,813
Accrued directors and advisors fees	27,000
Accrued audit and tax preparation	23,376	$ 93,500
Accrued clinical study expenses	19,773	22,777
Accrued legal professional fees	15,250	76,500
Accrued other	36,776	7,784
	$ 252,003	$ 359,374

Note 6 - Notes Payable, Relat30

Note 6 - Notes Payable, Related Parties (Details Textual) - USD ($)	Jun. 15, 2015	Mar. 31, 2016	Mar. 31, 2015	Jan. 13, 2016	Dec. 31, 2015
Health Tronics, Inc [Member] | Note Amendment [Member]
Related Party Transaction, Rate	8.00%
Related Party, Notes Payable Manditory Prepayment Rate	20.00%
Health Tronics, Inc [Member] | Class K Warrants [Member]
Class of Warrant or Right, Issued During Period	3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.55
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1
Class of Warrant or Right, Expiration Period	10 years
Health Tronics, Inc [Member]
Related Party Transaction, Rate		6.00%
Notes Payable, Related Parties, Noncurrent		$ 5,353,806			$ 5,348,112
Debt Instrument, Unamortized Discount		18,937			24,631
Common Stock, Par or Stated Value Per Share	$ 0.001
Interest Payable, Current		182,968			239,803
Interest Expense, Related Party		$ 152,713	$ 80,072
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.55
Notes Payable, Related Parties, Noncurrent					$ 5,348,112
Class of Warrant or Right, Issued During Period		34,001,041
Common Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001	$ 0.001

Note 7 - Promissory Notes Pay31

Note 7 - Promissory Notes Payable (Details Textual)	Feb. 01, 2016USD ($)shares	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)
8% Convertible Promissory Notes [Member] | During First Sixty Days [Member]
Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance	120.00%
8% Convertible Promissory Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 58,300
Proceeds from Each Convertible Debt, Gross	$ 53,000
Debt Instrument, Original Issuance Discount Percent	10.00%
Number Of Investors	2
Proceeds from Convertible Debt	$ 106,000
Debt Instrument, Prepayment Term	60 days
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	30.00%
Debt Instrument, Convertible, Threshold Trading Days	20
Debt Instrument, Term	180 days
Notes Payable, Current		$ 100,601
Debt Issuance Costs, Net		17,473
Class M Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares	1
Proceeds from Convertible Debt		106,000
Notes Payable, Current		$ 100,601

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual)	Mar. 31, 2016USD ($)
Operating Loss Carryforwards	$ 70,096,802

Note 9 - Equity Transactions (D

Note 9 - Equity Transactions (Details Textual)	Mar. 11, 2016USD ($)$ / sharesshares	Jan. 13, 2016$ / sharesshares	Mar. 31, 2016$ / sharesshares	Dec. 31, 2015$ / shares	Jun. 15, 2015$ / shares
The 2016 Equity Offering [Member] | Health Tronics, Inc [Member]
Related Party, Notes Payable Manditory Prepayment Rate	20.00%
The 2016 Equity Offering [Member] | Class L Warrants [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
The 2016 Equity Offering [Member] | Class L Warrants [Member]
Class of Warrant or Right, Issued During Period	25,495,835
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.08
The 2016 Equity Offering [Member]
Stock Issued During Period, Shares, New Issues	25,495,835
Proceeds from Issuance of Private Placement Gross | $	$ 1,529,750
Health Tronics, Inc [Member]
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.001
Class L Warrants [Member] | Newport Coast Securities, Inc. and Oppenheimer & Co. Inc. [Member] | The 2016 Equity Offering [Member]
Class of Warrant or Right, Issued During Period	2,549,584
Class L Warrants [Member]
Class of Warrant or Right, Issued During Period			28,045,419
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.08
Series A Warrants [Member] | Convertible Common Stock [Member]
Stock Issued During Period, Shares, New Issues		7,447,954
Warrants Converted During Period		23,701,428
Convertible Preferred Stock, Shares Issued upon Conversion		12,500
Series A Warrants [Member] | Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues		293
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.06		$ 0.06
Class of Warrant or Right, Exchange Ratio		0.4685
Common Stock, Ownership Threshold		9.99%
Subscription Agreement [Member] | On or before May 27, 2014 [Member]
Minimum Installment Amount Of Purchase Price | $	$ 100,000
Class of Warrant or Right, Issued During Period			34,001,041
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.001

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Jan. 13, 2016	Mar. 17, 2014	Mar. 31, 2016	Jan. 12, 2016	Jan. 06, 2016	Dec. 31, 2015	Mar. 14, 2014
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding					0
Preferred Stock, Shares Authorized							6,175
Preferred Stock, Par or Stated Value Per Share							$ 0.001
Preferred Stock, Stated Value Per Share							$ 1,000
Stock Issued During Period, Shares, New Issues		6,175
Undesignated Preferred Stock [Member]
Preferred Stock, Shares Outstanding			0			0
Preferred Stock, Shares Authorized			4,993,532			4,993,532
Preferred Stock, Par or Stated Value Per Share			$ 0.001			$ 0.001
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized				293
Preferred Stock, Par or Stated Value Per Share				$ 0.001
Preferred Stock, Stated Value Per Share				$ 1,000
Stock Issued During Period, Shares, New Issues	293
Convertible Preferred Stock, Shares Issued upon Conversion			2,000
Convertible Preferred Stock Beneficial Ownership Limitation Conversion Percentage			9.99%
Preferred Stock, Par or Stated Value Per Share	$ 0.001

Note 11 - Warrants (Details Tex

Note 11 - Warrants (Details Textual) - USD ($)	Mar. 31, 2016	Mar. 11, 2016	Feb. 01, 2016	Dec. 31, 2015	Jun. 15, 2015	Mar. 17, 2014	Feb. 10, 2014
Class J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06	$ 0.06
Warrants and Rights Outstanding	$ 20,500			$ 2,900			$ 12,776
Class M Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06	0.06
Warrants and Rights Outstanding	$ 76,300		$ 9,091
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06	$ 0.06
Warrants and Rights Outstanding	$ 9,900			$ 112,500
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.55
Warrants and Rights Outstanding	$ 16,100			22,700	$ 36,989
Series A and B Warrants [Member] | 18% Convertible Promissory Notes [Member]
Warrants and Rights Outstanding							$ 47,974
Series A and B Warrants [Member] | Private Placement [Member]
Warrants and Rights Outstanding						$ 557,733
8% Convertible Promissory Notes [Member]
Conversion Option of Debt Issued, Fair Value Disclosure			$ 66,331
Debt Instrument, Interest Rate, Stated Percentage			8.00%
18% Convertible Promissory Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage							18.00%
Warrants and Rights Outstanding	$ 122,800			$ 138,100

Note 11 - Warrant Activity (Det

Note 11 - Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2016shares
Class E Warrants [Member]
Warrants Outstanding (in shares)	3,576,737
Warrants Outstanding (in shares)	3,576,737
Class F Warrants [Member]
Warrants Outstanding (in shares)	300,000
Warrants Outstanding (in shares)	300,000
Class G Warrants [Member]
Warrants Outstanding (in shares)	1,503,409
Warrants Outstanding (in shares)	1,503,409
Class H Warrants [Member]
Warrants Outstanding (in shares)	1,988,095
Warrants Outstanding (in shares)	1,988,095
Class I Warrants [Member]
Warrants Outstanding (in shares)	1,043,646
Warrants Outstanding (in shares)	1,043,646
Class J Warrants [Member]
Warrants Outstanding (in shares)	629,378
Warrants Outstanding (in shares)	4,641,667
Warrants Issued (in shares)	4,012,289
Class K Warrants [Member]
Warrants Outstanding (in shares)	3,310,000
Warrants Outstanding (in shares)	3,310,000
Class L Warrants [Member]
Warrants Outstanding (in shares)	28,045,419
Warrants Issued (in shares)	28,045,419
Class M Warrants [Member]
Warrants Outstanding (in shares)	1,943,333
Warrants Issued (in shares)	1,943,333
Series A Warrants [Member]
Warrants Outstanding (in shares)	25,951,421
Warrants Outstanding (in shares)	2,249,994
Warrants Converted (in shares)	(23,701,427)
Warrants Outstanding (in shares)	38,302,686
Warrants Outstanding (in shares)	48,602,300
Warrants Issued (in shares)	34,001,041
Warrants Converted (in shares)	(23,701,427)

Note 11 - Warrant Exercise Pric

Note 11 - Warrant Exercise Price Per Share and Expiration Date (Details) - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 11, 2016
Class E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Expiration date	April 2,016
Class F Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.35
Expiration date	February 2,018
Class G Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class H Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class I Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.85
Expiration date	September 2,018
Class J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06	$ 0.06
Expiration date	February 2,019
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.55
Expiration date	June 2,025
Class L Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08
Expiration date	March 2,019
Class M Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06	0.06
Expiration date	February 2,021
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.06	$ 0.06
Expiration date	March 2,019

Note 11 - Changes in the Warran

Note 11 - Changes in the Warrant Liability (Details)	3 Months Ended
	Mar. 31, 2016USD ($)
Class J Warrants [Member]
Warrant liability	$ 2,900
Issued
Change in fair value	$ 17,600
Warrant liability	20,500
Class K Warrants [Member]
Warrant liability	$ 22,700
Issued
Change in fair value	$ (6,600)
Warrant liability	$ 16,100
Class M Warrants [Member]
Warrant liability
Issued	$ 75,422
Change in fair value	878
Warrant liability	76,300
Series A Warrants [Member]
Warrant liability	$ 112,500
Issued
Change in fair value	$ (102,600)
Warrant liability	9,900
Warrant liability	138,100
Issued	75,422
Change in fair value	(90,722)
Warrant liability	$ 122,800

Note 12 - Commitments and Con39

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating Leases, Rent Expense, Net	$ 42,519	$ 33,407

Note 13 - Stock-based Compens40

Note 13 - Stock-based Compensation (Details Textual) - USD ($)	Nov. 01, 2010	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Stock Incentive Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		12,500,000		12,500,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit		$ 0.06		$ 0.06
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit		$ 2		$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 0		$ 0
Allocated Share-based Compensation Expense		$ 4,500	$ 27,827
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term				7 years 167 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term		7 years 76 days

Note 13 - Option Activity (Deta

Note 13 - Option Activity (Details) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Outstanding, number (in shares)	10,073,385	10,073,385
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.55	$ 0.62
Exercisable (in shares)	9,898,383
Exercisable, weighted average exercise price per share (in dollars per share)	$ 0.56

Note 13 - Nonvested Options Act

Note 13 - Nonvested Options Activity (Details)	Mar. 31, 2016$ / sharesshares
Outstanding, number (in shares) | shares	175,002
Outstanding, weighted average exercise price per share (in dollars per share) | $ / shares	$ 0.36
Outstanding, number (in shares) | shares	175,002
Outstanding, weighted average exercise price per share (in dollars per share) | $ / shares	$ 0.36

Note 14 - Earnings (Loss) Per43

Note 14 - Earnings (Loss) Per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	62,332,963	42,199,516

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	Apr. 29, 2016	Apr. 15, 2016	Apr. 06, 2016	Mar. 11, 2016	Mar. 31, 2016	Apr. 30, 2016	Dec. 31, 2015
Subsequent Event [Member] | The 2016 Equity Offering [Member] | Class L Warrant Issued to Investors [Member]
Class of Warrant or Right, Issued During Period			4,520,835
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.08
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Subsequent Event [Member] | The 2016 Equity Offering [Member] | Class L Warrant, Issued to Placement Agent [Member]
Class of Warrant or Right, Issued During Period			452,083
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.08
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Subsequent Event [Member] | The 2016 Equity Offering [Member]
Stock Issued During Period, Shares, New Issues		1,437,501	3,083,334
Proceeds from Issuance of Private Placement Gross		$ 86,200	$ 185,000
Subsequent Event [Member] | Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	293					0
Stock Issued During Period, Shares, Conversion of Convertible Securities	3,657,278
The 2016 Equity Offering [Member]
Stock Issued During Period, Shares, New Issues				25,495,835
Proceeds from Issuance of Private Placement Gross				$ 1,529,750
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding					293		0
Class of Warrant or Right, Issued During Period					34,001,041